Avalyn Pharma Inc.
SEC CIK 1540171 · AVLN · last insider filing 2026-05-05
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Turner Heather D | Director | filed 2026–2026 |
| Carroll Jill | Director | filed 2026–2026 |
| Congleton Jon | Director | filed 2026–2026 |
| Haviland Kate | Director | filed 2026–2026 |
| Lavelle Erin | Director | filed 2026–2026 |
| Baranowski Lyn | Director · Chief Executive Officer | filed 2026–2026 |
| Friedman David Matthew | Director | filed 2026–2026 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Golden Adam H. | General Counsel | filed 2026–2026 |
| Carlson Douglas R | See Remarks | filed 2026–2026 |
| Rhodes Melissa | Chief Operating Officer | filed 2026–2026 |
| Lazarus Howard | Chief Medical Officer | filed 2026–2026 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.